1
Pedersen Jan T, Searle Stephen M J, Rees Anthony R, Roguska Michael A, Guild Braydon C: Resurfacing of rodent antibodies.. Immunogen, April 13, 1994: EP0592106-A1 (249 worldwide citation)

A method for determining how to humanize a rodent antibody or fragment thereof by resurfacing, said method comprising: (a) determining the conformational structure of the variable region of said rodent antibody or fragment thereof by constructing a three-dimensional model of said rodent antibody var ...


2
Leonard G Presta, Bradley R Snedecor: Altered polypeptides with increased half-life. Genentech, Janet E Hasak, April 14, 1998: US05739277 (217 worldwide citation)

Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.


3
Ota Toshio, Isogai Takao, Nishikawa Tetsuo, Hayashi Kohji, Saito Kaoru, Yamamoto Junichi, Ishii Shizuko, Sugiyama Tomoyasu, Wakamatsu Ai, Nagai Keiichi, Otsuki Tetsuji: Primers for synthesising full-length cdna and their use. Helix Res Inst, February 7, 2001: EP1074617-A2 (173 worldwide citation)

Primers for synthesizing full-length cDNAs and their use are provided. 5602 cDNA encoding a human protein has been isolated and nucleotide sequences of 5'-, and 3' -ends of the cDNA have been determined. Furthermore, primers for synthesizing the full-length cDNA have been provided to clarify the fun ...


4
Cerami Anthony, Kawakami Masanobu: Anabolic activity modulator and uses thereof.. Univ Rockefeller, March 4, 1987: EP0212489-A2 (154 worldwide citation)

A modulator material is disclosed which has been isolated from macrophage cells that have been incubated with a stimulator material from an invasive stimulus. The modulator material comprises a protein that exhibits the ability to substantially completely suppress the activity of the anabolic enzyme ...


5
Dumas Milne Edwards Jean Bapti, Duclert Aymeric, Giordano Jean Yves: Expressed sequence tags and encoded human proteins. Genset, September 6, 2000: EP1033401-A2 (135 worldwide citation)

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences ...


6
Wallach David, Engelmann Hartmut, Aderka Dan, Rubinstein Menachem: (tnf)Inhibitory protein and its purification.. Yeda Res & Dev, March 22, 1989: EP0308378-A2 (128 worldwide citation)

Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein, salts, functional derivatives and active fractions thereof and mixtures of any o ...


7
Becquart Jerome, Fleer Reinhard, Hirel Philippe Herve, Klatzmann David Robert, Landais Didier, Mayaux Jean Francois, Yeh Patrice: Albumin derivatives with therapeutic functions.. Rhone Poulenc Sante, February 20, 1991: EP0413622-A1 (124 worldwide citation)

Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules ...


8
Hakimi John, Kilian Patricia, Rosen Perry: Polyethylene glycol protein conjugates.. Hoffmann La Roche, October 28, 1992: EP0510356-A1 (123 worldwide citation)

The present invention relates to physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugates having at least part of the biological activity of the protein which forms the conjugate, without exhibiting the same disadvantageous immunogenic responses ther ...


9
Lauffer Leander Dr, Oquendo Patricia Dr, Zettlmeissl Gerd Dr, Seed Brian Dr: Fusionproteins with parts of immunoglobulins, their production and use.. Behringwerke, Gen Hospital, January 8, 1992: EP0464533-A1 (122 worldwide citation)

The invention relates to genetically engineered soluble fusion proteins consisting of human proteins or parts thereof not belonging to the immunoglobulin family and various portions of the constant region of immunoglobulin molecules. The functional properties of both fusion components are surprising ...


10
Wallach David: A monoclonal antibody recognizing a cytotoxin, a hybridoma cell line expressing same and a process for the preparation of a purified cytotoxin.. Yeda Res & Dev, July 9, 1986: EP0186833-A2 (121 worldwide citation)

A cytotoxic protein expressed by human peripheral blood mononuclear cells is isolated in essentially homogenous form. This protein may be used to elicit production of polyclonal or monoclonal anti-cytotoxin antibodies. Hybridomas secreting anti-cytotoxin antibodies are identified by a solid phase bi ...



Click the thumbnails below to visualize the patent trend.